The estimated Net Worth of Catherine A. Sohn is at least $3.78 Million dollars as of 11 August 2023. Catherine Sohn owns over 1,241 units of Jazz Pharmaceuticals plc stock worth over $1,563,073 and over the last 12 years he sold JAZZ stock worth over $1,672,602. In addition, he makes $542,573 as Independent Director at Jazz Pharmaceuticals plc.
Catherine has made over 24 trades of the Jazz Pharmaceuticals plc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 1,241 units of JAZZ stock worth $171,457 on 11 August 2023.
The largest trade he's ever made was exercising 12,500 units of Jazz Pharmaceuticals plc stock on 4 November 2020 worth over $742,500. On average, Catherine trades about 1,215 units every 65 days since 2012. As of 11 August 2023 he still owns at least 14,868 units of Jazz Pharmaceuticals plc stock.
You can see the complete history of Catherine Sohn stock trades at the bottom of the page.
Dr. Catherine Angell Sohn Pharm.D. serves as Independent Director of the Company. Dr. Sohn serves as an independent director on the boards of directors of three public companies: Axcella Health Inc., a biotechnology company, Landec Corporation, a life sciences company, and Rubius Therapeutics, a biotechnology company. She also serves as Chairperson of the board of BioEclipse Therapeutics, Inc., a privately-held clinical-stage biopharmaceutical company. From January 2014 to May 2017, Dr. Sohn served as an independent director on the board of directors of Neuralstem, Inc., a publicly-traded life sciences company. From 1998 to 2010, she was Senior Vice President, Worldwide Business Development and Strategic Alliances at GlaxoSmithKline Consumer Healthcare. From 1994 to 1998, she was Vice President, Worldwide Strategic Product Development at SmithKline Beecham Pharmaceuticals plc in the pharmaceutical division. From 1982 to 1994, she held a series of positions in Medical Affairs, Pharmaceutical Business Development and U.S. Product Marketing at SmithKline Beecham Pharmaceuticals plc and its predecessor, Smith, Kline & French. Dr. Sohn holds the position of Adjunct Professor at the University of California, San Francisco. She received a Doctor of Pharmacy from the University of California, San Francisco, School of Pharmacy and a Certificate of Professional Development from the Wharton School at the University of Pennsylvania.
As the Independent Director of Jazz Pharmaceuticals plc, the total compensation of Catherine Sohn at Jazz Pharmaceuticals plc is $542,573. There are 15 executives at Jazz Pharmaceuticals plc getting paid more, with Bruce Cozadd having the highest compensation of $14,713,600.
Catherine Sohn is 67, he's been the Independent Director of Jazz Pharmaceuticals plc since 2012. There are no older and 28 younger executives at Jazz Pharmaceuticals plc.
Catherine's mailing address filed with the SEC is C/O ALTIMMUNE, INC., 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG, MD, 20878.
Over the last 17 years, insiders at Jazz Pharmaceuticals plc have traded over $1,513,676,247 worth of Jazz Pharmaceuticals plc stock and bought 1,319,315 units worth $25,188,964 . The most active insiders traders include Michael W Michelson, Patrick G Enright, and Jp Iii Llckkr Partners Iii,.... On average, Jazz Pharmaceuticals plc executives and independent directors trade stock every 11 days with the average trade being worth of $5,162,934. The most recent stock trade was executed by Mary Elizabeth Henderson on 6 September 2024, trading 1,410 units of JAZZ stock currently worth $152,703.
jazz pharmaceuticals plc (nasdaq: jazz) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. we are a diverse company of over 875 employees focused on portfolio of products and/or product candidates in the areas of sleep, hematology/oncology and pain. founded in 2003 and headquartered in dublin, ireland, jazz pharmaceuticals has u.s. offices in palo alto, ca and philadelphia, pa, and has offices in various other locations in europe. the company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what is done to accomplish results by operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. we plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our uni
Jazz Pharmaceuticals plc executives and other stock owners filed with the SEC include: